27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
- Adverum Biotechnologies Inc (NASDAQ:ADVM) announced new long-term data from the OPTIC trial of ADVM-022 gene therapy for neovascular or wet age-related macular degeneration (wet AMD).
- Data were shared at the Retina Society's Annual Scientific Meeting.
- The 2 x 10^11 vg/eye dose (n=15), planned to be evaluated in a future Phase 2 trial, showed an over 80% reduction in annualized anti-VEGF injection frequency in patients who previously required frequent injections.
- Over 50% of patients after a median follow-up of 1.7 years remained entirely free of any supplemental anti-VEGF injection.
- Retinal anatomy (mean Central subfield thickness versus baseline) to improved and vision (mean BCVA versus baseline) was maintained over time.
- All ADVM-022-related ocular adverse events were mild (81%) to moderate (19%) across all wet AMD patients.
- At the 2 x 10^11 vg/eye dose, ocular inflammation was minimal and responsive to steroid eye drops.
- The Company plans to present INFINITY trial data in diabetic macular edema at the American Society of Retina Specialists Annual Scientific Meeting.
- Related: Adverum Stock Falls As It Stops Testing Ocular Gene Therapy Candidate In Diabetic Macular Edema Patients.
- Price Action: ADVM stock is up 6.88% at $2.33 during the premarket session on the last check Monday.
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!